In this section
@article{Jaggi:2024:10.1183/13993003.00803-2024,
author = {Jaggi, TK and Agarwal, R and Tiew, PY and Shah, A and Lydon, EC and Hage, CA and Waterer, GW and Langelier, CR and Delhaes, L and Chotirmall, SH},
doi = {10.1183/13993003.00803-2024},
journal = {Eur Respir J},
title = {Fungal lung disease.},
url = {http://dx.doi.org/10.1183/13993003.00803-2024},
volume = {64},
year = {2024}
}
TY - JOUR
AB - Fungal lung disease encompasses a wide spectrum of organisms and associated clinical conditions, presenting a significant global health challenge. The type and severity of disease are determined by underlying host immunity and infecting fungal strain. The most common group of diseases are associated with the filamentous fungus Aspergillus species and include allergic bronchopulmonary aspergillosis, sensitisation, aspergilloma and chronic and invasive pulmonary aspergillosis. Fungal lung disease remains epidemiologically heterogenous and is influenced by geography, environment and host comorbidities. Diagnostic modalities continue to evolve and now include novel molecular assays and biomarkers; however, persisting challenges include achieving rapid and accurate diagnosis, particularly in resource-limited settings, and in differentiating fungal infection from other pulmonary conditions. Treatment strategies for fungal lung diseases rely mainly on antifungal agents but the emergence of drug-resistant strains poses a substantial global threat and adds complexity to existing therapeutic challenges. Emerging antifungal agents and increasing insight into the lung mycobiome may offer fresh and personalised approaches to diagnosis and treatment. Innovative methodologies are required to mitigate drug resistance and the adverse effects of treatment. This state-of-the-art review describes the current landscape of fungal lung disease, highlighting key clinical insights, current challenges and emerging approaches for its diagnosis and treatment.
AU - Jaggi,TK
AU - Agarwal,R
AU - Tiew,PY
AU - Shah,A
AU - Lydon,EC
AU - Hage,CA
AU - Waterer,GW
AU - Langelier,CR
AU - Delhaes,L
AU - Chotirmall,SH
DO - 10.1183/13993003.00803-2024
PY - 2024///
TI - Fungal lung disease.
T2 - Eur Respir J
UR - http://dx.doi.org/10.1183/13993003.00803-2024
UR - https://www.ncbi.nlm.nih.gov/pubmed/39362667
VL - 64
ER -
For any enquiries related to the MRC Centre please contact:
Scientific Manager
Susannah Fisher
mrc.gida@imperial.ac.uk
External Relationships and Communications Manager
Dr Sabine van Elsland
s.van-elsland@imperial.ac.uk